Houston researcher secures $1.7M to develop drug for aggressive form of breast cancer

cancer research

Wei Wang, a UH College of Pharmacy research associate professor, is helping to develop a new targeted drug to treat triple-negative breast cancer. Photo courtesy UH.

A University of Houston researcher has joined a $3.2 million effort to develop a new drug designed to attack a cancer-driving protein commonly found in triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is one of the most difficult-to-treat forms of cancer and accounts for 10 percent to 15 percent of all breast cancer cases. The disease gets its name because tumors associated with it test negative for estrogen receptors, progesterone receptors and excess HER2 protein, making it difficult to target. Due to this, TNBC is often treated with general chemotherapy, which can come with negative side effects and drug resistance, according to UH.

UH College of Pharmacy research associate professor Wei Wang is developing a drug that can target the disease more specifically. The drug will target MDM2, a protein often overproduced in TNBC that also contributes to faster tumor growth.

Wang is working on a team led by Wei Li, director of the University of Tennessee Health Science Center College of Pharmacy’s Drug Discovery Center. She has received $1.7 million to support the research.

Wang and UH professor of pharmacology and toxicology Ruiwen Zhang have discovered a compound that can break down MDM2. In early laboratory models, the compound has shown the ability to shrink tumors.

Wang and Zhang will focus on understanding how the treatment works and monitoring its effectiveness in models that closely mirror human disease.

“We will study how the drug targets MDM2 and evaluate the most promising drug candidates to determine effective dosing, understand how the drug behaves in the body, compare it with existing treatments and assess early safety,” Wang said in a news release.

Li’s team at the University of Tennessee will be working on the chemistry and drug design end of the project.

“This work could lead to an entirely new class of therapies for triple-negative breast cancer,” Li added in the release. “We’re hopeful that by directly removing the MDM2 protein from cancer cells, we can help more patients respond to treatment regardless of their tumor type.”

From Your Site Articles
MD Anderson is teaming up with TOPPAN Holdings on cutting-edge organoid tech to help match cancer patients with the most effective treatments. Photo via Getty Images.

MD Anderson launches $10M collaboration to advance personalized cancer treatment tech

fighting cancer

The University of Texas MD Anderson Cancer Center and Japan’s TOPPAN Holdings Inc. have announced a strategic collaboration to co-develop TOPPAN Holdings’ 3D cell culture, or organoid, technology known as invivoid.

The technology will be used as a tool for personalized cancer treatments and drug screening efforts, according to a release from MD Anderson. TOPPAN has committed $10 million over five years to advance the joint research activities.

“The strategic alliance with MD Anderson paves a promising path toward personalized cancer medicine," Hiroshi Asada, head of the Business Innovation Center at TOPPAN Holdings, said in a news release.

Invivoid is capable of establishing organoid models directly from patient biopsies or other tissues in a way that is faster and more efficient. Researchers may be able to test a variety of potential treatments in the laboratory to understand which approach may work best for the patient, if validated clinically.

“Organoids allow us to model the three-dimensional complexity of human cancers in the lab, thus allowing us to engineer a powerful translational engine—one that could not only predict how patients will respond to therapy before treatment begins but also could help to reimagine how we discover and validate next-generation therapies," Dr. Donna Hansel, division head of pathology and laboratory medicine at MD Anderson, added in the news release. “Through this collaboration, we hope to make meaningful progress in modeling cancer biology for therapeutic innovation.”

The collaboration will build upon preclinical research previously conducted by MD Anderson and TOPPAN. The organizations will work collaboratively to obtain College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) certifications for the technology, which demonstrate a commitment to high-quality patient care. Once the certifications are obtained, they plan to conduct observational clinical studies and then prospective clinical studies.

“We believe our proprietary invivoid 3D cell culture technology, by enabling the rapid establishment of organoid models directly from patient biopsies, has strong potential to help identify more effective treatment options and reduce the likelihood of unnecessary therapies,” Asada added in the release. “Through collaboration on CAP/CLIA certification and clinical validation, we aim to bring this innovation closer to real-world patient care and contribute meaningfully to the advancement of cancer medicine."

Rice University's Lei Li has been awarded a $550,000 NSF CAREER Award to develop wearable, hospital-grade medical imaging technology. Photo by Jeff Fitlow/ Courtesy Rice University

Rice University professor earns $550k NSF award for wearable imaging tech​

science supported

Another Houston scientist has won one of the highly competitive National Science Foundation (NSF) CAREER Awards.

Lei Li, an assistant professor of electrical and computer engineering at Rice University, has received a $550,000, five-year grant to develop wearable, hospital-grade medical imaging technology capable of visualizing deep tissue function in real-time, according to the NSF. The CAREER grants are given to "early career faculty members who demonstrate the potential to serve as academic models and leaders in research and education."

“This is about giving people access to powerful diagnostic tools that were once confined to hospitals,” Li said in a news release from Rice. “If we can make imaging affordable, wearable and continuous, we can catch disease earlier and treat it more effectively.”

Li’s research focuses on photoacoustic imaging, which merges light and sound to produce high-resolution images of structures deep inside the body. It relies on pulses of laser light that are absorbed by tissue, leading to a rapid temperature rise. During this process, the heat causes the tissue to expand by a fraction, generating ultrasound waves that travel back to the surface and are detected and converted into an image. The process is known to yield more detailed images without dyes or contrast agents used in some traditional ultrasounds.

However, current photoacoustic systems tend to use a variety of sensors, making them bulky, expensive and impractical. Li and his team are taking a different approach.

Instead of using hundreds of separate sensors, Li and his researchers are developing a method that allows a single sensor to capture the same information via a specially designed encoder. The encoder assigns a unique spatiotemporal signature to each incoming sound wave. A reconstruction algorithm then interprets and decodes the signals.

These advances have the potential to lower the size, cost and power consumption of imaging systems. The researchers believe the device could be used in telemedicine, remote diagnostics and real-time disease monitoring. Li’s lab will also collaborate with clinicians to explore how the miniaturized technology could help monitor cancer treatment and other conditions.

“Reducing the number of detection channels from hundreds to one could shrink these devices from bench-top systems into compact, energy-efficient wearables,” Li said in the release. “That opens the door to continuous health monitoring in daily life—not just in hospitals.”

Amanda Marciel, the William Marsh Rice Trustee Chair of chemical and biomolecular engineering and an assistant professor at Rice, received an NSF CAREER Award last year. Read more here.

The Rice Biotech Launch Pad has named two bioengineering professors to its leadership team. Photo courtesy Rice University.

Rice biotech accelerator appoints 2 leading researchers to team

Launch Pad

The Rice Biotech Launch Pad, which is focused on expediting the translation of Rice University’s health and medical technology discoveries into cures, has named Amanda Nash and Kelsey L. Swingle to its leadership team.

Both are assistant professors in Rice’s Department of Bioengineering and will bring “valuable perspective” to the Houston-based accelerator, according to Rice.

“Their deep understanding of both the scientific rigor required for successful innovation and the commercial strategies necessary to bring these technologies to market will be invaluable as we continue to build our portfolio of lifesaving medical technologies,” Omid Veiseh, faculty director of the Launch Pad, said in a news release.

Amanda Nash

Nash leads a research program focused on developing cell communication technologies to treat cancer, autoimmune diseases and aging. She previously trained as a management consultant at McKinsey & Co., where she specialized in business development, portfolio strategy and operational excellence for pharmaceutical and medtech companies. She earned her doctorate in bioengineering from Rice and helped develop implantable cytokine factories for the treatment of ovarian cancer. She holds a bachelor’s degree in biomedical engineering from the University of Houston.

“Returning to Rice represents a full-circle moment in my career, from conducting my doctoral research here to gaining strategic insights at McKinsey and now bringing that combined perspective back to advance Houston’s biotech ecosystem,” Nash said in the release. “The Launch Pad represents exactly the kind of translational bridge our industry needs. I look forward to helping researchers navigate the complex path from discovery to commercialization.”

Kelsey L. Swingle

Swingle’s research focuses on engineering lipid-based nanoparticle technologies for drug delivery to reproductive tissues, which includes the placenta. She completed her doctorate in bioengineering at the University of Pennsylvania, where she developed novel mRNA lipid nanoparticles for the treatment of preeclampsia. She received her bachelor’s degree in biomedical engineering from Case Western Reserve University and is a National Science Foundation Graduate Research Fellow.

“What draws me to the Rice Biotech Launch Pad is its commitment to addressing the most pressing unmet medical needs,” Swingle added in the release. “My research in women’s health has shown me how innovation at the intersection of biomaterials and medicine can tackle challenges that have been overlooked for far too long. I am thrilled to join a team that shares this vision of designing cutting-edge technologies to create meaningful impact for underserved patient populations.”

The Rice Biotech Launch Pad opened in 2023. It held the official launch and lab opening of RBL LLC, a biotech venture creation studio in May. Read more here.

Sentinel BioTherapeutics is developing cytokine interleukin-2 (IL-2) capsules to fight many solid tumors. Photo via Getty Images.

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

A team of researchers at the University of Houston is working to develop a new treatment for Rhabdomyosarcoma, an aggressive cancer with a higher incidence in young children. Photo via Getty Images.

UH research team receives grant to fight aggressive pediatric cancer

cancer research

Researchers at the University of Houston have received a $3.2 million grant from the National Institutes of Health to help find innovative ways to treat Rhabdomyosarcoma, or RMS.

According to a statement from the university, RMS is a malignant soft tissue sarcoma that has a higher incidence in young children and is responsible for 8 percent of pediatric cancer cases with a relatively low survival rate.

One way UH is working on the issue is by studying how and why RMS cells, which are found most often in muscle tissue, divide uncontrollably without ever maturing into normal muscle cells. The researchers aim to tackle a target inside RMS cells known as TAK1, which plays a key role in regulating cell growth.

“By targeting TAK1, we aim to stop the cancer at its source and help the cells develop normally,” Ashok Kumar, the Else and Philip Hargrove Endowed Professor of Drug Discovery at the UH College of Pharmacy and director of the Institute of Muscle Biology and Cachexia, said in a news release. “This approach could lead to new and better treatments for RMS.”

According to UH, preliminary results demonstrated that TAK1 is highly activated in embryonal RMS cells, which are found in younger children; alveolar RMS cells, which are found in older children and teens; and human RMS samples. This suggests that the protein plays a major role in the development of this form of cancer.

The team still aims to uncover how the protein helps RMS cancer grow and plans to evaluate how blocking TAK1 can be used as a therapeutic.

“Blocking TAK1, either by changing the genes (genetic approaches) or using drugs (pharmacological approaches), can stop certain harmful behaviors in cancer cells,” Kumar added. “This was tested both in lab-grown cells and in living models, showing that TAK1 is a key target to control RMS cancer’s spread and aggressiveness, and inhibits tumor formation.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Texas earns 22nd 'best state for business' title as GDP hits $2.9T

booming economy

The Texas business sector recently received a double dose of good news.

For the 22nd consecutive year, Chief Executive magazine named Texas the best state for business. In tandem with that achievement, preliminary new estimates from the U.S. Bureau of Economic Analysis show the size of Texas’ economy jumped to $2.9 trillion in 2025, up by a nation-leading growth rate of 2.5 percent compared with the previous year.

Speaking about the Chief Executive honor, Gov. Greg Abbott says Texas benefits from pro-growth policies, a strong workforce, strategic investments in education, training for high-demand skills and the presence of critical infrastructure.

“Texas is where businesses innovate and where opportunity abounds. … We will continue to move at the speed of business as we build a more prosperous Texas for generations to come,” the governor says.

An annual Chief Executive survey of CEOs, presidents and business owners determines which state is the best for business. Texas has landed at No. 1 every year since Chief Executive launched the ranking.

“Truly, this is an incredible run that Texas has going,” says Christopher Chalk, publisher of Chief Executive. “CEOs are a tough group to please, and yet year after year Texas continues to earn the top spot—no small feat.”

It’s also no small feat for a state to notch annual gains in its gross domestic product (GDP), a measurement of economic power based on the value of goods and services produced each year.

With an estimated GDP of $2.9 trillion last year, Texas maintains its position as the eighth-largest global economy compared with the nations of the world, based on preliminary estimates from the International Monetary Fund.

In reference to Texas’ GDP growth, Abbott says the Lone Star State is “the premier destination for job creators from across the country and world. We will keep attracting world-class investment, create jobs, and expand opportunity for Texans for generations to come.”

UH med school granted $2M gift to offer student scholarships

scholarship gift

A new scholarship endowment aims to support students in the University of Houston’s recently established medical school.

The University of Houston’s Tilman J. Fertitta Family College of Medicine received a planned estate gift commitment estimated at $2.1 million to establish the Bob Diehl and Teresa Evans Diehl Scholarship Endowment. The scholarship will assist full-time medical students who demonstrate financial need and meet academic standards.

“Endowed scholarships like this do more than ease the burden of tuition—they empower our students to focus on learning, leadership and compassionate care,” Jonathan McCullers, UH vice president of health affairs and dean of the Fertitta College of Medicine, said in a news release. “We are deeply grateful to the Diehls for their vision and commitment to expanding access to health care through education.”

The endowment aims to provide annual scholarship support for students enrolled in the Fertitta College of Medicine. The gift also aligns with the university's fundraising initiative focused on expanding opportunities for students, known as Can’t Stop Houston: The Centennial Campaign, which works to expand research ahead of UH’s 100th anniversary next year.

The Diehls are both graduates from UH, and Bob Diehl spent 38 years working at UPS.

“It brings me happiness to know that my endowment will make a difference in young people's lives and in the communities that will need those future doctors,” he said in the release.

The Fertitta College of Medicine welcomed its inaugural class of 30 students in 2020 and expects classes to grow to 120 students in the coming years, according to UH. The university believes scholarship opportunities will be crucial for students to pursue medical education despite financial challenges.

“The Diehl family’s generosity will open doors for talented future physicians who are called to serve our communities but may otherwise face financial barriers to pursuing a medical education,” McCullers added.

9 Houston universities boast best grad programs of 2026, per U.S. News

making the grade

Nine Houston-area universities are earning new national acclaim in a report of the best graduate schools in the U.S. for 2026.

U.S. News & World Report annually publishes its national "Best Graduate Schools" rankings in early April, which comprehensively rank graduate programs across business, education, engineering, law, health, and many others.

New for the 2026 edition, the publication updated its rankings across 12 health disciplines — only physician assistant and social work were excluded — and "the first full refresh" of doctoral science programs since 2022. U.S. News also revived its Master's in Fine Arts rankings for the first time since 2020.

"We know a graduate degree is a major commitment,” said LaMont Jones, Ed.D., managing editor of Education at U.S. News. “That is why we are dedicated to methodologies that thoroughly examine a wide range of factors, from research excellence to career success. These rankings are a powerful tool for prospective students, offering clarity and confidence as they approach their most critical educational choice."

This is how the nine local schools ranked, statewide and nationally, and how they compared with last year's national ranking:

Rice University

  • Brown School of Engineering – No. 3 best graduate engineering school in Texas; No. 25 nationally (up from No. 26 last year)
  • Jones Graduate School of Business – No. 3 best business school in Texas; No. 29 nationally (unchanged)

Several of Rice’s doctoral science programs were among the 30 best in the country, including earth sciences (No. 20), chemistry (No. 22), biostatistics (No. 25), mathematics (No. 26), statistics (No. 27), and physics (No. 28). The Ph.D. biological sciences program tied as 55th best nationwide. Rice’s public affairs program tied for No. 107 nationally.

University of Houston

  • Cullen College of Engineering – No. 5 best graduate engineering school in Texas; tied for No. 71 nationally (up from No. 72 last year)
  • College of Education – No. 5 best graduate education school in Texas; No. 95 nationally (down from No. 81 last year)
  • UH Law Center – No. 5 best law school in Texas; No. 54 nationally (up from No. 63 last year)

The University of Houston has the 31st best pharmacy program in the country, its speech-language pathology program tied for No. 54 nationally, and the clinical psychology program tied as 65th best in the U.S. In the doctoral sciences rankings, UH’s earth sciences program ranked No. 80 nationally, the physics program tied for No. 81, the chemistry program ranked 84th, and the mathematics program ranked No. 87. The Ph.D. biological sciences program ranked as the 104th best in the nation. UH’s public affairs program tied as 80th best nationally. The university also has the 106th best fine arts program in the nation.

University of Houston, Clear Lake

  • College of Education – No. 12 best graduate education school in Texas; No. 164 nationally (up from No. 166 last year)

University of Texas Health Science Center (UT Health Houston)

  • Cizik School of Nursing – No. 2 best master’s in nursing program in Texas; No. 32 nationally (up from No. 41 last year)
  • McGovern Medical School – Tier 2 best research medical school in the U.S.

UT Health Houston’s public health program tied for No. 31 nationwide, and the health care management program tied for No. 47. The Cizik School of Nursing’s nurse anesthesia program tied as 49th best in the country. In the doctoral sciences rankings, the university’s biostatistics program tied as the 25th best nationwide.

University of Texas Medical Branch, Galveston

  • Sealy School of Medicine – Tier 2 best medical research school in the U.S.

UT Medical Branch’s occupational therapy program tied for No. 41 nationally, the physical therapy program tied for No. 57, and the university tied for the 60th best nurse anesthesia program in the U.S. The public health program tied for No. 89 nationally. In the doctoral sciences rankings, the university’s biostatistics program tied for No. 70 nationally.

Prairie View A&M University

  • College of Nursing – No. 5 best master’s in nursing program in Texas; No. 104 nationally (unchanged)

South Texas College of Law Houston

  • No. 7 best law school in Texas; No. 128 nationally (up from No. 138 last year)

Texas Southern University

  • College of Education – No. 17 best graduate education school in Texas; No. 219 nationally (down from No. 178-195 last year)

TSU’s pharmacy program tied for No. 120 nationally.

University of Texas MD Anderson
UT MD Anderson’s doctoral biostatistics program tied as the 17th best nationally, and the doctoral biological sciences program tied for No. 50.

---

This article originally appeared on CultureMap.com.

View All Listings